Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.140
+0.010 (0.47%)
At close: Feb 11, 2026, 4:00 PM EST
2.170
+0.030 (1.40%)
After-hours: Feb 11, 2026, 4:04 PM EST

Xenetic Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
2.862.52.541.711.160.44
Revenue Growth (YoY)
13.30%-1.56%48.80%47.06%165.64%2460.31%
Gross Profit
2.862.52.541.711.160.44
Selling, General & Admin
2.843.423.563.653.743.4
Research & Development
3.333.293.494.773.161.73
Operating Expenses
6.176.77.068.426.915.13
Operating Income
-3.31-4.2-4.52-6.72-5.75-4.69
Interest & Investment Income
0.160.250.360.170.10.13
Other Non Operating Income (Expenses)
-0-0.010.03-00-0
EBT Excluding Unusual Items
-3.16-3.96-4.13-6.55-5.65-4.57
Asset Writedown
------9.24
Pretax Income
-3.16-3.96-4.13-6.55-5.65-13.81
Income Tax Expense
------2.92
Net Income
-3.16-3.96-4.13-6.55-5.65-10.89
Net Income to Common
-3.16-3.96-4.13-6.55-5.65-10.89
Shares Outstanding (Basic)
222111
Shares Outstanding (Diluted)
222111
Shares Change (YoY)
0.11%0.86%7.44%38.38%60.81%124.10%
EPS (Basic)
-2.05-2.57-2.71-4.61-5.49-17.04
EPS (Diluted)
-2.05-2.57-2.71-4.61-5.49-17.04
Free Cash Flow
-2.72-2.82-4.11-4.65-4.74-4.27
Free Cash Flow Per Share
-1.76-1.83-2.69-3.27-4.61-6.67
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-115.80%-168.16%-177.78%-393.57%-495.12%-1074.41%
Profit Margin
-110.40%-158.39%-162.78%-383.87%-486.36%-2493.11%
Free Cash Flow Margin
-95.07%-112.69%-161.98%-272.23%-408.21%-976.60%
EBITDA
-----5.75-4.69
D&A For EBITDA
----00
EBIT
-3.31-4.2-4.52-6.72-5.75-4.69
EBIT Margin
-115.80%-168.16%-177.78%---
Revenue as Reported
2.862.52.541.711.160.44
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q